Transdermal Optical Imaging (TOI) as a Non-invasive Measure to Detect Changes in Hydration Status in Healthy Adults and Athletes

NCT ID: NCT06212518

Last Updated: 2024-01-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-02

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to analyze smart phone-based Transdermal Optical Imaging (TOI) features to develop a model that can discern hydration status, including: 1) at various timepoints throughout a 24-hour period in healthy adults from the general population (GENPOP), and 2) before and after a team coach-led training session in athletes competing in a sport (ATHLETE). TOI data will be collected alongside standard reference measures of hydration status.

In this study each subject will serve as their own control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dehydration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GENPOP passive dehydration

In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)). Participants will be provided pre-filled water bottles and asked to only ingest fluid in bottle until second morning face scan.

Group Type EXPERIMENTAL

GENPOP fluid restriction

Intervention Type OTHER

In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).

GENPOP ad libitum fluid intake

No fluid restriction

Group Type EXPERIMENTAL

GENPOP ad libitum fluid intake

Intervention Type OTHER

Unrestricted fluid intake.

ATHLETE with fluid restriction

For 24 hours prior to the study session, encouraged to drink sufficient fluid to maintain euhydration. Asked to refrain from alcohol 24 hours prior to session. Not permitted to drink during training session.

Group Type EXPERIMENTAL

ATHLETE restricted fluid intake

Intervention Type OTHER

Not permitted to drink during training session.

ATHLETE ad libitum fluid intake

For 24 hours prior to the study session, encouraged to drink sufficient fluid to maintain euhydration. Asked to refrain from alcohol 24 hours prior to session. Permitted to drink during training session.

Group Type EXPERIMENTAL

ATHLETE ad libitum fluid intake

Intervention Type OTHER

No restriction on fluid intake

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GENPOP ad libitum fluid intake

Unrestricted fluid intake.

Intervention Type OTHER

GENPOP fluid restriction

In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).

Intervention Type OTHER

ATHLETE ad libitum fluid intake

No restriction on fluid intake

Intervention Type OTHER

ATHLETE restricted fluid intake

Not permitted to drink during training session.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Both Study Arms (GENPOP and ATHLETE)

* Subject is male or female
* If female, subject is not pregnant
* Subject is willing to avoid alcohol consumption 24 hours prior to visit(s)
* Subject is willing to avoid wearing makeup to the study session or willing to remove it with facial wipes before the face scans
* Subject is willing to shave facial hair if predetermined during the informed consent session it will interfere with TOI measurement
* Able to speak, write, and read English
* Provision of written consent to participate

GENPOP Study

* Study subject is 18-65 years of age, inclusive
* Subject does not smoke (or has quit for at least 6 months)
* Subject is not taking medication that may interfere with the study
* Subject has no health conditions that would prevent completion of the trial as indicated on the general health questionnaire (GHQ)
* Subject is willing to fast overnight (\~8-12 hours)
* Subject is willing to refrain from vigorous exercise for 48 hours
* Subject is willing to eat the exact same food the day prior to each visit to the testing site

ATHLETE Study

* Study subject is 14-45 years of age, inclusive
* Subject is participating in team sport training/competition
* Subject is participating in a coach-led practice

Exclusion Criteria

Both Study Arms (GENPOP and ATHLETE)

* Subject has participated or currently enrolled in a clinical trial within the past 30 days
* Subject has participated in any PepsiCo trial within past 6 months
* Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk
* Subject is allergic to alcohol or facial cleansing wipes
* Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.

GENPOP Study

• Subject has a health condition or is taking medication that can be worsened by fluid restriction (participants who opt-in to fluid restriction study arm only)
Minimum Eligible Age

14 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

PepsiCo Global R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lindsay Baker, PhD

Role: STUDY_DIRECTOR

PepsiCo, Inc. Sports Science

Matt Hinkley, PhD

Role: PRINCIPAL_INVESTIGATOR

Pepsico, Inc. Sports Science

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pepsico R&D Life Sciences

Bradenton, Florida, United States

Site Status RECRUITING

PepsiCo R&D Gatorade Sports Science Institute

Chicago, Illinois, United States

Site Status RECRUITING

PepsiCo R&D, Gatorade Sports Science Institute

Valhalla, New York, United States

Site Status RECRUITING

PepsiCo R&D, Gatorade Sports Science Institute

Plano, Texas, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Matthew Hinkley, PhD

Role: CONTACT

914-742-4975

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Khalil Lee, PhD

Role: primary

334-728-0250

Matthew Hinkley, PhD

Role: backup

914-742-4975

Shellen Goltz, PhD

Role: primary

312-821-3317

Matthew Hinkley, PhD

Role: backup

914-742-4975

Matthew Hinkley, PhD

Role: primary

914-742-4975

Anthony Wolfe, MS

Role: primary

469-920-2862

Matthew Hinkley, PhD

Role: backup

914-742-4975

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PEP-2306 3b

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Body Water Content Sensor
NCT00643721 TERMINATED
TRK-3 Performance of Pachymetry
NCT06250868 COMPLETED
Point-spectroscopy Trial
NCT05183698 UNKNOWN
InBody Validation Study
NCT02635958 COMPLETED